Key considerations for developing U.S. pricing strategies for innovative oncology therapies
While not a new subject, the rising cost of cancer care is leading to increased emphasis on value-based care and heightened scrutiny of oncology launch pricing. Therefore, a broad, multistakeholder perspective is required to inform a manufacturer’s launch price and corresponding rationale. In addition, activities related to preparing the market, communicating the value proposition and optimizing access must align to best position a product for success.
During this webinar, our hosts — Megan Lambert, Nicholas Economides and Don Creighton (Huron’s life sciences business), as well as clinical pharmacist Filiz Yucebay (Huron’s healthcare business and provider implementation solutions) outlined their key considerations for developing U.S. pricing strategies for innovative oncology therapies and discussed its perspective on the topics above based on their 40 years of combined experience in pricing, across both industry and consulting.
